1-3 of 3
Vladimir Lj Lazarevic
Close
Sort by
Journal Articles

Impact of treatment delay in acute myeloid leukemia revisited

Clinical Trials & Observations
Gunnar Juliusson, Oskar Hagberg, Vladimir Lj Lazarevic, Sören Lehmann, Martin Höglund
Journal: Blood Advances
Blood Adv (2021) 5 (3): 787–790.
https://doi.org/10.1182/bloodadvances.2020003806
Published: 2021
Includes: Supplemental data
Journal Articles

The prognostic impact of FLT3 -ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting

Clinical Trials & Observations
Gunnar Juliusson, Martin Jädersten, Stefan Deneberg, Sören Lehmann, Lars Möllgård, Lovisa Wennström, Petar Antunovic, Jörg Cammenga, Fryderyk Lorenz, Emma Ölander, Vladimir Lj Lazarevic, Martin Höglund
Journal: Blood Advances
Blood Adv (2020) 4 (6): 1094–1101.
https://doi.org/10.1182/bloodadvances.2019001335
Published: 2020
Includes: Supplemental data
Journal Articles

Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells

Mia Eriksson, Pablo Peña-Martínez, Ramprasad Ramakrishnan, Marion Chapellier, Carl Högberg, Gabriella Glowacki, Christina Orsmark-Pietras, Talía Velasco-Hernández, Vladimir Lj Lazarević, Gunnar Juliusson, Jörg Cammenga, James C. Mulloy, Johan Richter, Thoas Fioretos, Benjamin L. Ebert, Marcus Järås
Journal: Blood Advances
Blood Adv (2017) 1 (23): 2046–2057.
https://doi.org/10.1182/bloodadvances.2017006148
Published: 2017
Includes: Supplemental data